Oppenheimer Reiterates Outperform on MediWound, Maintains $63 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on MediWound (NASDAQ:MDWD) and maintains a $63 price target.
May 31, 2023 | 11:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on MediWound and maintains a $63 price target.
The reiteration of an Outperform rating by Oppenheimer analyst Francois Brisebois indicates a positive outlook for MediWound's stock. The maintained $63 price target suggests that the analyst believes the stock has potential for growth in the short term. This news is likely to have a positive impact on MDWD's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100